Open Access. Powered by Scholars. Published by Universities.®
Social and Behavioral Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Social and Behavioral Sciences
The Extracellular Chaperone Clusterin Influences Amyloid Formation And Toxicity By Interacting With Pre-Fibrillar Structures, Justin Yerbury, Stephen Poon, Sarah Meehan, Brianna Thompson, Janet Kumita, Christopher Dobson, Mark Wilson
The Extracellular Chaperone Clusterin Influences Amyloid Formation And Toxicity By Interacting With Pre-Fibrillar Structures, Justin Yerbury, Stephen Poon, Sarah Meehan, Brianna Thompson, Janet Kumita, Christopher Dobson, Mark Wilson
Mark R Wilson
Clusterin is an extracellular chaperone present in all disease-associated extracellular amyloid deposits, however, its roles in amyloid formation and protein deposition in vivo are poorly understood. The current study initially aimed to characterise the effects of clusterin on amyloid formation in vitro by a panel of eight protein substrates. Two of the substrates (Alzheimer's beta peptide and a PI3-SH3 domain) were then used in further experiments to examine the effects of clusterin on amyloid cytotoxicity and to probe the mechanism of clusterin action. We show that clusterin exerts potent effects on amyloid formation, the nature and extent of which vary …
The Extracellular Chaperone Clusterin Potently Inhibits Human Lysozyme Amyloid Formation By Interacting With Prefibrillar Species, Mark Wilson, Justin Yerbury, Stephen Poon, Christopher Dobson, C V Robinson, Elise Stewart, Janet Kumita, Mireille Dumoulin, Gemma Caddy, Christine Hagan
The Extracellular Chaperone Clusterin Potently Inhibits Human Lysozyme Amyloid Formation By Interacting With Prefibrillar Species, Mark Wilson, Justin Yerbury, Stephen Poon, Christopher Dobson, C V Robinson, Elise Stewart, Janet Kumita, Mireille Dumoulin, Gemma Caddy, Christine Hagan
Mark R Wilson
We have studied the effects of the extracellular molecular chaperone, clusterin, on the in vitro aggregation of mutational variants of human lysozyme, including one associated with familial amyloid disease. The aggregation of the amyloidogenic variant I56T is inhibited significantly at clusterin-to-lysozyme ratios as low as 1:80 (i.e. one clusterin molecule per 80 lysozyme molecules). Experiments indicate that under the conditions where inhibition of aggregation occurs, clusterin does not bind detectably to the native or fibrillar states, or to the monomeric transient intermediate known to be a key species in the aggregation reaction. Rather, it seems to interact with oligomeric species …